> The Mechanism of Effort Intolerance in Patients with Peripheral Arterial Disease: a Combined Stress Echocardiography and Cardiopulmonary Exercise Test

Eihab Ghantous MD, Aviel Shetrit MD, Yonatan Erez MD, Ryan S. Zamanzadeh BS, David Zahler MD, Yoav Granot MD, Erez Levi MD, Michal Laufer Perl MD, Shmuel Banai MD, Yan Topilsky MD and Ofer Havakuk MD

From the Cardiology division, Tel Aviv Sourasky Medical Center, affiliated to Tel Aviv University, Tel Aviv, Israel

Correspondence: Ofer Havakuk MD

Cardiology division Tel Aviv Sourasky Medical Center 6 Weissman Street Tel Aviv 64239, Israel E-mail: havakukofer@gmail.com

Funding/support: No.

Conflict of interest: No.

Short title: The Mechanism of Effort Intolerance in Peripheral Arterial Disease.

Word count: 3941.

Abstract:

Background: Data to delineate exercise intolerance in patients with peripheral arterial disease (PAD) are scarce. We used a combined stress echocardiography and cardiopulmonary exercise test (CPET) to explore effort intolerance in PAD.

Methods: Twenty-eight patients who had both PAD and coronary artery disease (CAD) were compared with sex and age-matched 31 CAD patients and 15 normal controls using a symptom-limited ramp bicycle CPET on a tilting dedicated ergometer. Echocardiographic images were obtained concurrently with gas exchange measurements along predefined stages of exercise. Oxygen extraction was calculated using the Fick equation: (VO2)/(echocardiography-calculated cardiac output) at each activity level.

Results: Along stages of exercise (unloaded; anaerobic threshold; peak), in PAD+CADF patients compared with CAD or controls: diastolic function worsened (E/e' 13.2 \pm 3.1 vs 9.3 \pm 2.4 vs 9.6 \pm 4; 16.6 \pm 4.3 vs 10.4 \pm 2.5 vs 9.1 \pm 3.8; 15.8 \pm 4 vs 11.9 \pm 2.9 vs 9.1 \pm 4.1), and oxygen consumption (6.1 \pm 1.4 vs 5.8 \pm 1.9 vs 6.5 \pm 2.5; 14.2 \pm 1.8 vs 17.1 \pm 2.9 vs 18.1 \pm 3.3; 14.9 \pm 2 vs 19.3 \pm 2.5 vs 22 \pm 3.6 ml/kg/min) and oxygen pulse (6.5 \pm 1.9 vs 6.5 \pm 2 vs 6.6 \pm 2.3; 8.2 \pm 1.8 vs 10 \pm 2.4 vs 8.1 \pm 2.3; 8.1 \pm 2.2 vs 11.1 \pm 2 vs 11.7 \pm 2.6ml/beat) were reduced. Notably, oxygen pulse was blunted due to an insufficient increase in both stroke volume (89 \pm 11 vs 92 \pm 11 vs 92 \pm 13; 95 \pm 10 vs 104 \pm 9 vs 103 \pm 11; 86 \pm 10 vs 97 \pm 10 vs 98 \pm 11ml) and oxygen extraction (0.06 \pm 0.03 vs 0.07 \pm 0.03 vs 0.07 \pm 0.03; 0.09 \pm 0.03 vs 0.12 \pm 0.03 vs 0.12 \pm 0.03; 0.09 \pm 0.03 vs 0.13 \pm 0.03 vs 0.13 \pm 0.031/l). Chronotropic incompetence was more prevalent in PAD patients and persisted after correction for beta-blockers use (62% vs 42% and 11% respectively). Reduced ventilatory efficiency (peak VE/VCO2 36.8 \pm 4.9 vs 31.5 \pm 4 vs 30.5 \pm 51/l) and reduced mechanical efficiency (slope of oxygen consumption/work rate 8.96 \pm 0.42 vs 10.37 \pm 0.41 vs 10.8 \pm 0.491/W) were found.

Conclusion: Exercise limitation is affected by diastolic dysfunction, chronotropic incompetence and peripheral factors in PAD patients.

Non-standard Abbreviations and Acronyms:

SE – stress echocardiography

CPET - cardiopulmonary exercise test

VO2 – Oxygen consumption

VCO2 - carbon-dioxide production

VE/VCO2 - ratio of ventilation to carbon-dioxide production

RER - respiratory exchange ratio

AV difference - arteriovenous oxygen extraction

Clinical perspectives:

Peripheral arterial disease (PAD) is characterized by exercise intolerance. Yet, the mechanism behind this limitation is not well characterized. We show here that effort limitation in PAD is caused by a combination of central and peripheral cardiovascular factors including diastolic dysfunction, chronotropic incompetence and insufficient peripheral muscle oxygen extraction. These data may assist targeting future therapeutic measures.

Introduction:

Peripheral arterial disease (PAD) affects 6.5% of people aged 50-55 years in the western world and its prevalence reaches 13% in those aged 70-75 years. ^{1, 2} PAD is associated with a significant risk for cardiovascular outcomes, but is mainly characterized by effort intolerance which is usually associated with lower extremity pain. ^{1, 2} Nevertheless, studies exploring the mechanism behind effort intolerance in PAD are limited and therefore, it is difficult to delineate its drivers and to suggest targeted therapies. Here, we investigated effort intolerance in PAD with the use of a combined stress echocardiography (SE) and cardiopulmonary exercise test (CPET). Due to the high prevalence of coronary artery disease (CAD) in PAD patients ^{3, 4} and in order to adequately evaluate the effect of PAD, we used both CAD patients and normal controls as references.

Methods:

Study population:

> Consecutive PAD patients who also had CAD (i.e >70% obstructive epicardial coronary lesion⁵) underwent combined SE with CPET as part of investigation for effort intolerance at our center. Diagnosis of PAD was based on the following: extracranial carotid artery stenosis>50%, abdominal aortic aneurysm, ankle-brachial index (ABI)<0.9 or the need for peripheral arterial revascularization.¹ Patients were excluded from the study if they could not complete the exercise test (i.e. respiratory exchange ratio (RER)<1, n=7), had an abnormal echocardiographic exam (i.e. \geq moderate valvular heart disease (n=2), a left ventricular ejection fraction \leq 40% (n=4)) or had severe pulmonary disease (n=1), leaving a total of 28 patients for the analysis ("PAD+CAD group"). Two groups of age and sex-matched patients who were referred for effort dyspnea assessment during the study period were used as controls: (I) patients with established CAD (of whom, 4 were excluded due to an inadequate exercise test and 4 were excluded due to abnormal rest echocardiography), leaving a total of 31 CAD patients ("CAD group"), and (II) 15 normal controls. All study participants were ambulatory and stable. The trial was approved by our local ethic committee and all patients signed an informed consent.

Study protocol:

The study protocol included a combined SE with CPET and was previously described.⁶

Cardiopulmonary exercise test:

A symptom-limited graded ramp bicycle exercise test was performed in the semisupine position on a tilting dedicated microprocessor controlled eddy current brake SE cycle ergometer (Ergoselect 1000 L, CareFusion, San Diego, California). Expected peak oxygen consumption (VO₂ max) was the highest averaged 30-sec VO₂ during exercise and was estimated on the basis of patients' age, height, and weight. Work rate increment necessary to reach patients' estimated VO₂ max in 8 to 12 minutes was then calculated. The protocol included 3 minutes of unloaded pedaling, a symptom-limited ramp graded exercise, and 2 minutes of recovery. Breath-by-breath minute ventilation, carbon dioxide production (VCO₂), and oxygen consumption (VO₂) were measured using a Medical Graphics metabolic cart (ZAN, nSpire Health Inc., Oberthulba, Germany). The RER was defined as the ratio between VCO₂ and VO₂ obtained from ventilatory expired gas analysis.⁷ Anaerobic threshold (AT) was

determined manually using the modified V-slope method. Patients were encouraged to continue baseline medical therapy. In patients on beta-blocker therapy, chronotropic incompetence was determined when <62% of heart rate (HR) reserve was used.⁸

Stress echocardiography:

Rest stage echocardiographic images were taken before cycling. Then, echocardiographic images were obtained concurrently with breath-by-breath gas exchange measurements in a continuous manner along predefined stages of exercise: rest; unloaded cycling; AT; and peak exercise (i.e. VO2 max). Each cycle of imaging included left ventricular end-diastolic and end-systolic volumes, stroke volume (SV), peak E- and A-wave velocities, deceleration time, and septal e', and lasted 30 to 60 sec. LV end-diastolic volume, end-systolic volume, and ejection fraction (EF) were calculated according to the single plane ellipsoid apical 4 chamber area-length method. Left atrial volume was calculated according to the biplane area-length method.⁹ SV was calculated by multiplying the LVOT area at rest by the LV outflow tract velocity-time integral measured by pulsed-wave Doppler during each activity level. All echocardiographic measurements were done using manual tracing.⁹ Echocardiographic data were then analyzed retrospectively at different exercise stages. Unloaded stage images were taken during unloaded exercise. AT (and the heart rate (HR) at the AT) were determined manually and retrospectively using the gas exchange measurements and the modified V-slope method. On the basis of HR at the AT echocardiogram, data were analyzed from the images captured immediately after reaching the HR at the AT. Peak exercise images were defined as those captured immediately after reaching RER >1.05.⁷ Arterio-venous oxygen extraction (A $-VO_2$) was calculated using the Fick equation as follows: $(VO_2)/(echocardiography$ calculated CO) at each activity level.¹⁰

Statistical analysis:

Categorical variables were summarized as frequency and percentage. Continuous variables were described as median and IQR. In order to compare clinical, echocardiographic and metabolic parameters in patients with PAD+CAD vs CAD or normal controls, the groups were first matched according to age and sex. McNemar test was used to compare categorical variables and Wilcoxon test was done to

compare continuous variables. To analyze the differences at the different stages of effort, we used the repeated-measures linear model analysis to define the within-group effect for each parameter over time, the between group differences over time, and the group by time interactions. All statistical tests were two sided and p<0.05 was considered as statistically significant. SPSS software was used for all statistical analyses (IBM SPSS statistic for Windows, version 27, IBM corp., ARMONK, NY, USA, 2020)

Results:

The study group comprised 28 PAD+CAD patients. Mean age was 74.5 \pm 7.1, 81% men, 92% had a history of smoking, mean LVEF was 52 \pm 6.3% and mean estimated glomerular filtration rate was 61.4 \pm 8.1ml/min. Differences in baseline characteristics between PAD+CAD patients and either CAD patients or normal controls are shown in Table 1. Notably, baseline LVEF (52.1 \pm 6.3 vs 57.3 \pm 4.5 vs 62.1 \pm 4.1%, p=0.021 and p<0.001), diastolic function (E/E' ratio: 12.1 \pm 2.7 vs 10.2 \pm 2.4 vs 8.3 \pm 3.1, p=0.023 and p=0.012) and pulmonary function tests (% predicted forced expiratory volume in 1 sec: 79.1 \pm 16.8 vs 94 \pm 15 vs 96.2 \pm 17.7, p=0.03 and p=0.035) were worse in PAD+CAD group vs CAD or normal controls, respectively.

Along stages of exercise (unloaded; anaerobic threshold; peak), comparing PAD+CAD patients vs CAD or controls: Cardiac output was reduced (7.4 \pm 2 vs 7.5 \pm 2.1 vs 7.8 \pm 3.1 p=0.78 and p=0.39; 9.3 \pm 2.7 vs 10.3 \pm 2.4 vs 11.9 \pm 2.8 p=0.10 and p=0.002; 10.5 \pm 2.9 vs 12.7 \pm 2.2 vs 13.2 \pm 31, p=0.032 and p=0.0011) due to a combination of blunted stroke volume increase (89 \pm 11 vs 92 \pm 11 vs 92 \pm 13, p=0.7 and p=0.61; 95 \pm 10 vs 104 \pm 9 vs 103 \pm 11, p=0.042 and p=0.051; 86 \pm 10 vs 97 \pm 10 vs 98 \pm 11ml, p=0.036 and p=0.039), impeded diastolic function (E/e' 13.2 \pm 3.1 vs 9.3 \pm 2.4 vs 9.6 \pm 4, p=0.0014 and p=0.007; 16.6 \pm 4.3 vs 10.4 \pm 2.5 vs 9.1 \pm 3.8, p<0.001 and p<0.001; 15.8 \pm 4 vs 11.9 \pm 2.9 vs 9.1 \pm 4.11/m p=0.0027 and p<0.001) and diminished heart rate reserve (82 \pm 12.6 vs 86.3 \pm 13.2 vs 88.1 \pm 14, p=0.28 and p=0.19; 97.3 \pm 14.1 vs 99.6 \pm 13.3 vs 116.7 \pm 15, p=0.4 and p=0.0013; 107.7 \pm 17.2 vs 119.8 \pm 14.4 vs 138.5 \pm 18.9bpm, p=0.035 and p<0.001) which persisted after correction for betablockers use (chronotropic incompetence was present in 62% vs 42% and 11% of PAD+CAD vs CAD patients or controls, p=0.038 and p<0.001 respectively) (Table 2,

Figure 1, 2). Furthermore, oxygen consumption was reduced (6.1 ± 1.4 vs 5.8 ± 1.9 vs 6.5 ± 2.5 , p=0.26 and p=0.19; 14.2 ± 1.8 vs 17.1 ± 2.9 vs 18.1 ± 3.3 , p=0.029 and p=0.0012; 14.9 ± 2 vs 19.3 ± 2.5 vs 22 ± 3.6 ml/kg/min, p<0.001 and p<0.001) and oxygen pulse was blunted (6.5 ± 1.9 vs 6.5 ± 2 vs 6.6 ± 2.3 , p=0.91 and p=0.63; 8.2 ± 1.8 vs 10 ± 2.4 vs 9.8 ± 2.3 , p=0.064 and p=0.085; 8.1 ± 2.2 vs 11.1 ± 2 vs 11.7 ± 2.6 ml/beat, p=0.0021 and p<0.001) not only due to an insufficient increase in stroke volume, but also because of a reduced oxygen extraction (0.06 ± 0.03 vs 0.07 ± 0.03 vs 0.07 ± 0.03 , p=0.22 and p=0.29; 0.09 ± 0.03 vs 0.12 ± 0.03 vs 0.12 ± 0.03 , p=0.041 and p=0.049; 0.09 ± 0.03 vs 0.13 ± 0.03 vs 0.13 ± 0.03 l/l, p=0.0015 and p=0.002) (Table 2, Figure 1). Reduced ventilatory efficiency (peak VE/VCO2 36.8 ± 4.9 vs 31.5 ± 4 vs 30.5 ± 5 respectively, p=0.0031 and p=0.0018) and reduced mechanical efficiency (slope of oxygen consumption/work rate 8.96 ± 0.42 vs 10.37 ± 0.41 vs 10.8 ± 0.49 respectively, p<0.001 and p<0.001, Figure 3) were found.

Discussion:

Using an elaborate protocol, we have demonstrated here that exercise limitation in PAD is associated with a combination of central and peripheral cardiovascular factors including diastolic dysfunction, diminished heart rate reserve and limited muscle oxygen extraction.

PAD is characterized by effort intolerance which is often associated with intermittent claudication and leg pain.¹¹ This intuitive association is strengthened by the beneficial effect of exercise training on walking distance and symptom improvement.¹² Nevertheless, despite this clinical improvement, exercise training has little effect on indices of peripheral arterial function, such as ABI.¹³ This apparent contradiction might be settled given our findings showing that not only peripheral, but also cardiac factors are involved in the cardiovascular limitation in PAD.

Diastolic dysfunction:

PAD patients suffer from high prevalence of cardiovascular risk factor including diabetes mellitus and hypertension.^{1, 2} Furthermore, CAD often coincides with PAD.^{4, 14} All are in association with diastolic dysfunction. Nevertheless, baseline echocardiographic indices often do not fulfill diagnostic criteria for diastolic

dysfunction in PAD patients.¹⁵ Studies exploring effort intolerance etiologies have shown that diastolic dysfunction could be unmasked by exercise.¹⁶ Our findings suggesting "concealed" diastolic dysfunction in PAD which is exposed by exercise are in concordance with these results and may shed light on the attenuation in stroke volume and CO increase shown here. Notably, despite an overall similar risk profile in our CAD group, a diastolic limitation was less common in this group, suggesting that PAD+CAD patients may suffer from a higher prevalence of microvascular myocardial disease which may contribute to stress-induced diastolic dysfunction.¹⁷

Peripheral oxygen extraction:

Notwithstanding the important effect of CO on oxygen uptake along the exercise, we have shown here that peripheral oxygen extraction was reduced in PAD+CAD patients and contributed to oxygen uptake attenuation. A signal for this limitation was demonstrated as early as the unloaded pedaling phase. The importance and the contribution of peripheral oxygen extraction to total oxygen uptake increases as CO decreases¹⁸ and requires normal peripheral microvasculature and mitochondrial function, both compromised in PAD.¹⁹ Consequently, the combination of stroke volume attenuation shown here together with reduced peripheral oxygen extraction augments the limitation in total oxygen consumption and in exercise capacity in PAD.

Mechanical efficiency:

The combination of exercise-induced diastolic dysfunction, blunting of cardiac output and reduced peripheral oxygen extraction also corresponds with the reduced ratio of oxygen uptake to workload in PAD+CAD patients found in our study. Usually, a constant ratio of $\Delta O2/\Delta W$ (usually around 10.5-11) is found in both normal and cardiovascular patients undergoing CPET studies. Nevertheless, a reduced ratio of $\Delta O2/\Delta W$ characterizes high-risk patients (e.g. severe heart failure, pulmonary vascular disease) and might be caused from the presence of microvascular dysfunction, a change in the ratio of muscle fiber type or mitochondrial dysfunction. Different studies have shown that microvascular dysfunction is prevalent in PAD.^{20, 21} Furthermore, both pathology-based studies^{22, 23} and magnetic resonance imaging^{24, 25} have demonstrated a change in muscle characteristics and in mitochondrial function in PAD. Our results highlight these findings and emphasize the complex relationship between central and peripheral factors in PAD.

Chronotropic incompetence:

We have demonstrated here that PAD+CAD patients suffer from a high prevalence of chronotropic incompetence (CI). CI was repeatedly shown to be associated with increased morbidity and mortality in cardiovascular patients²⁶ and in this sense, our findings may shed light on another potential contributor to the poor outcomes shown in PAD. Additionally, CI is an important determinant of cardiac output and maximal oxygen consumption²⁷⁻²⁹ and further explains effort intolerance in PAD. Animal and human studies have demonstrated that PAD is associated with an increased sympathetic tone.^{30, 31} This may partially explain the limited "sympathetic reserve" and consequently, the CI which was observed here.

Our findings may contribute to potential therapeutic interventions in PAD. The main method of exercise training in PAD is supervised exercise program (SEP), which has demonstrated symptomatic improvement, improved quality of life and increased walking distance in PAD.³² It involves, however, at least 2-hours of weekly exercise for a 12-week period and therefore requires adherence which is not often achieved.³³ A potential alternative, high intensity interval training (HIIT), which was found beneficial in heart failure and in CAD, was not adequately evaluated in PAD.³⁴ It will be interesting to explore the potential cardiac vs peripheral cardiovascular effects of these two methods, an approach which may shed further light on our findings and their interpretation. Furthermore, our results showing a "concealed" diastolic dysfunction in PAD may imply that novel therapeutics (e.g. type 2 sodium glucose transporter inhibitors^{35, 36}) might prove to be beneficial in PAD. Similarly, the presence of microvascular dysfunction is highly likely in PAD and could be addressed by novel therapeutics.^{37, 38} Last, the CI demonstrated here was also found in HF and could be potentially mitigated by exercise training or implantable devices.

Our study has several limitations. First, we used a noninvasive approach for CO and filling pressures measurements and we calculated anaerobic threshold according to gas exchange alone. Nevertheless, our approach enabled us to examine "real-life" patients without the bias of including only those who agree to undergo an invasive procedure. Furthermore, the use of simultaneous echocardiography enabled us to measure dynamic changes in cardiac chambers' size and in valvular function. Second, our study group was comprised of PAD+CAD patients and not PAD alone. We

believe, however, that the very high prevalence of CAD in PAD patients cannot be ignored and our approach makes our findings more translational to everyday clinical practice. Third, our age and sex-matched normal control group was comprised of elderly patients with low-intermediate prevalence of cardiovascular risk factors. Nevertheless, comparing our high-risk study group with a group of young and healthy controls might have damaged the validity of our findings.

In conclusion, using a comprehensive cardiopulmonary and stress echo test, we have demonstrated that exercise intolerance in PAD is associated with diastolic dysfunction, chronotropic incompetence and reduced peripheral oxygen extraction. Further studies are needed to establish targeted therapeutic approaches which might mitigate these limitations.

Figure legends:

Figure 1 – Along stages of exercise, oxygen consumption was reduced in PAD patients due to a combination of mechanical and peripheral limitations.

P* - PAD+CAD vs CAD, $P^{\#}$ - PAD+CAD vs Normal controls.

Figure 2 – Compared with either CAD patients or normal controls, a higher prevalence of chronotropic incompetence was found among PAD+CAD patients.

Figure 3 – A decreased ratio of oxygen consumption to work rate was shown in PAD+CAD patients compared with either CAD patients or normal controls.

References:

 Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D and Walsh ME. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2017;135:e726-e779.
Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I and Group ESCSD. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). *Eur Heart J.* 2018;39:763-816.

3. Calvet D, Touze E, Varenne O, Sablayrolles JL, Weber S and Mas JL. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: the PRECORIS study. *Circulation*. 2010;121:1623-9.

4. Vidakovic R, Schouten O, Kuiper R, Hoeks SE, Flu WJ, van Kuijk JP, Goei D, Verhagen HJ, Neskovic AN and Poldermans D. The prevalence of polyvascular disease in patients referred for peripheral arterial disease. *Eur J Vasc Endovasc Surg.* 2009;38:435-40.

5. Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, Fremes SE, Gaudino MF, Goldberger ZD, Grant MC, Jaswal JB, Kurlansky PA, Mehran R, Metkus TS, Nnacheta LC, Rao SV, Sellke FW, Sharma G, Yong CM and Zwischenberger BA. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145:e18-e114.

6. Shimiaie J, Sherez J, Aviram G, Megidish R, Viskin S, Halkin A, Ingbir M, Nesher N, Biner S, Keren G and Topilsky Y. Determinants of Effort Intolerance in Patients With Heart Failure: Combined Echocardiography and Cardiopulmonary Stress Protocol. *JACC Heart Fail*. 2015;3:803-14.

7. Guazzi M, Adams V, Conraads V, Halle M, Mezzani A, Vanhees L, Arena R, Fletcher GF, Forman DE, Kitzman DW, Lavie CJ, Myers J, European Association for Cardiovascular P, Rehabilitation and American Heart A. EACPR/AHA Scientific Statement. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. *Circulation*. 2012;126:2261-74.

8. Brubaker PH and Kitzman DW. Chronotropic incompetence: causes, consequences, and management. *Circulation*. 2011;123:1010-20.

9. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W and Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39 e14.

10. Haykowsky MJ, Brubaker PH, Stewart KP, Morgan TM, Eggebeen J and Kitzman DW. Effect of endurance training on the determinants of peak exercise oxygen consumption in elderly patients with stable compensated heart failure and preserved ejection fraction. *J Am Coll Cardiol*. 2012;60:120-8.

11. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T and Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. *Eur J Vasc Endovasc Surg.* 2009;38:463-74.

12. Al-Jundi W, Madbak K, Beard JD, Nawaz S and Tew GA. Systematic review of homebased exercise programmes for individuals with intermittent claudication. *Eur J Vasc Endovasc Surg.* 2013;46:690-706.

13. Lane R, Ellis B, Watson L and Leng GC. Exercise for intermittent claudication. *Cochrane Database Syst Rev.* 2014:CD000990.

14. Hofmann R, Kypta A, Steinwender C, Kerschner K, Grund M and Leisch F. Coronary angiography in patients undergoing carotid artery stenting shows a high incidence of significant coronary artery disease. *Heart*. 2005;91:1438-41.

15. Yamasaki S, Izawa A, Shiba Y, Tomita T, Miyashita Y, Koyama J and Ikeda U. Presence of diastolic dysfunction in patients with peripheral artery disease. *Angiology*. 2013;64:540-3.

16. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V and Borlaug BA. Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. *Circulation*. 2017;135:825-838.

17. Taqueti VR, Solomon SD, Shah AM, Desai AS, Groarke JD, Osborne MT, Hainer J, Bibbo CF, Dorbala S, Blankstein R and Di Carli MF. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. *Eur Heart J*. 2018;39:840-849.

18. Tanabe Y, Nakagawa I, Ito E and Suzuki K. Hemodynamic basis of the reduced oxygen uptake relative to work rate during incremental exercise in patients with chronic heart failure. *Int J Cardiol.* 2002;83:57-62.

19. McDermott MM, Ferrucci L, Gonzalez-Freire M, Kosmac K, Leeuwenburgh C, Peterson CA, Saini S and Sufit R. Skeletal Muscle Pathology in Peripheral Artery Disease: A Brief Review. *Arterioscler Thromb Vasc Biol.* 2020;40:2577-2585.

20. Beckman JA, Duncan MS, Damrauer SM, Wells QS, Barnett JV, Wasserman DH, Bedimo RJ, Butt AA, Marconi VC, Sico JJ, Tindle HA, Bonaca MP, Aday AW and Freiberg MS. Microvascular Disease, Peripheral Artery Disease, and Amputation. *Circulation*. 2019;140:449-458.

21. Rossi M and Carpi A. Skin microcirculation in peripheral arterial obliterative disease. *Biomed Pharmacother*. 2004;58:427-31.

22. McDermott MM, Hoff F, Ferrucci L, Pearce WH, Guralnik JM, Tian L, Liu K, Schneider JR, Sharma L, Tan J and Criqui MH. Lower extremity ischemia, calf skeletal muscle characteristics, and functional impairment in peripheral arterial disease. *J Am Geriatr Soc*. 2007;55:400-6.

23. Kosmac K, Gonzalez-Freire M, McDermott MM, White SH, Walton RG, Sufit RL, Tian L, Li L, Kibbe MR, Criqui MH, Guralnik JM, T SP, Leeuwenburgh C, Ferrucci L and Peterson CA. Correlations of Calf Muscle Macrophage Content With Muscle Properties and Walking Performance in Peripheral Artery Disease. *J Am Heart Assoc.* 2020;9:e015929.

24. Lin YC, Chuang WY, Wei FC, Yeh CH, Tinhofer I, Al Deek NF, Fu TC, Ng SC, Chang TC, Cheung YC, Ng SH and Juan YH. Peripheral arterial disease: the role of extracellular volume measurements in lower limb muscles with MRI. *Eur Radiol*. 2020;30:3943-3950.

25. Pipinos, II, Shepard AD, Anagnostopoulos PV, Katsamouris A and Boska MD. Phosphorus 31 nuclear magnetic resonance spectroscopy suggests a mitochondrial defect in claudicating skeletal muscle. *J Vasc Surg*. 2000;31:944-52.

26. Zweerink A, van der Lingen ACJ, Handoko ML, van Rossum AC and Allaart CP. Chronotropic Incompetence in Chronic Heart Failure. *Circ Heart Fail*. 2018;11:e004969.

27. Topilsky Y, Rozenbaum Z, Khoury S, Pressman GS, Gura Y, Sherez J, Man A, Shimiaie J, Edwards S, Berookhim J, Le Tourneau T, Halkin A, Biner S, Keren G and Aviram G. Mechanisms of Effort Intolerance in Patients With Heart Failure and Borderline Ejection Fraction. *Am J Cardiol.* 2017;119:416-422.

28. Haykowsky MJ, Brubaker PH, John JM, Stewart KP, Morgan TM and Kitzman DW. Determinants of exercise intolerance in elderly heart failure patients with preserved ejection fraction. *J Am Coll Cardiol*. 2011;58:265-74.

29. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC and Kass DA. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. *Circulation*. 2006;114:2138-47.

30. Stone AJ and Kaufman MP. The exercise pressor reflex and peripheral artery disease. *Auton Neurosci.* 2015;188:69-73.

31. Li J and Xing J. Muscle afferent receptors engaged in augmented sympathetic responsiveness in peripheral artery disease. *Front Physiol*. 2012;3:247.

32. Lane R, Harwood A, Watson L and Leng GC. Exercise for intermittent claudication. *Cochrane Database Syst Rev.* 2017;12:CD000990.

33. Harwood AE, Smith GE, Cayton T, Broadbent E and Chetter IC. A Systematic Review of the Uptake and Adherence Rates to Supervised Exercise Programs in Patients with Intermittent Claudication. *Ann Vasc Surg.* 2016;34:280-9.

34. Pymer S, Harwood A, Ibeggazene S, McGregor G, Huang C, Twiddy M, Nicholls AR, Ingle L, Carroll S, Long J, Rooms M, Chetter IC and group Ii. High INtensity Interval Training In pATiEnts with intermittent claudication (INITIATE): protocol for a multicentre, proof-of-concept, prospective interventional study. *BMJ Open*. 2020;10:e038825.

35. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, Brunner–La Rocca H-P, Choi D-J, Chopra V, Chuquiure-Valenzuela E, Giannetti N, Gomez-Mesa JE, Janssens S, Januzzi JL, Gonzalez-Juanatey JR, Merkely B, Nicholls SJ, Perrone SV, Piña IL, Ponikowski P, Senni M, Sim D, Spinar J, Squire I, Taddei S, Tsutsui H, Verma S, Vinereanu D, Zhang J, Carson P, Lam CSP, Marx N, Zeller C, Sattar N, Jamal W, Schnaidt S, Schnee JM, Brueckmann M, Pocock SJ, Zannad F and Packer M. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. *New England Journal of Medicine*. 2021;385:1451-1461.

36. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang C-E, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M and Langkilde AM. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. *New England Journal of Medicine*. 2022;387:1089-1098.

 Godo S, Suda A, Takahashi J, Yasuda S and Shimokawa H. Coronary Microvascular Dysfunction. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2021;41:1625-1637.
Bairey Merz CN, Pepine CJ, Shimokawa H and Berry C. Treatment of coronary microvascular dysfunction. *Cardiovascular Research*. 2020;116:856-870.

Table 1: Baseline (rest) characteristics

	PAD+CAD	CAD Norr		n value	n value
	n=28	n=31	Controls	PAD+CAD	PAD+CAD
	11 20	11 51	n=15	vs CAD	vs Normal
Age years	74 5+7 1	72 9+6 8	74+7.7	0.21	0.86
Male %	81	78	75	0.17	0.09
PAD involvement %:	01	NA	NA	NA	NA
CAS	29	1.11	1111	1111	
AAA	15				
Ilio-femoral	25				
Low ABI	72				
SBP, mmHg	145±8	138±8	133±11	0.06	0.03
Heart rate, bpm	71.1±4.3	72.5±5	78.7±7.2	0.82	0.10
BMI, kg/m^2	27.8±5.2	27.3±5.1	28.8	0.47	0.31
Current smoker. %	31	14	17	0.01	0.042
Past smoker, %	61	17	19	< 0.001	< 0.001
Hypertension, %	71	74	65	0.56	0.33
Diabetes mellitus, %	38	28	22	0.13	0.016
Hyperlipidemia, %	85	87	47	0.78	0.012
Atrial fibrillation, %	21	14	15	0.08	0.085
Creatinine, mg/dl	1.53±0.46	1.07±0.27	1.13±0.39	0.029	0.022
Hemoglobin, g/dl	15.1±2.1	14.7±1.8	14.1±2.7 0.29		0.31
Beta-blockers, %	76	68	26 0.22		0.0014
ACEI, %	60	65	68	0.2	0.26
Antiplatelet, %	88	92	12	0.6	< 0.001
Statins, %	92	97	40	0.73	< 0.001
EDV index, ml/ m^2	68±9	67.1±10.6	67.5±11.5	0.54	0.71
ESV index, ml/m ²	26±8.4	25.2±8.7	24.9±8.9	0.81	0.63
Stroke volume, ml	73.3±8.1	71.5±8.5	74.3±10.7	0.36	0.74
Cardiac output, l/min	5.4±0.9	5.2±0.85	5.4±1.05	0.29	0.9
LVEF, %	52.1±6.3	57.3±4.5	62.1±4.1	0.047	0.001
LVMI, g/m ²	97.8±26.1	94.9±24.7	94.3±27	0.43	0.71
LAVI, ml/ m ²	24.3±6.8	21.2±5.9	20.6±5.1	0.15	0.11
E wave, m/sec	0.64±0.13	0.53±0.1	0.57±0.16	0.08	0.46
A wave, m/sec	0.66±0.06	0.61±0.13	0.55±0.1	0.19	0.04
E wave DT, m/sec	204±50	199±47	201±58	0.58	0.62
E'. cm/sec	7.5±2.3	9.0±2.1	9.7±3.1	0.17	0.07
E/E' ratio	12.1±2.7	10.2±2.4	8.3±3.1	0.18	0.013
S', cm/sec	8.2±1.8	9.4±1.9	9.4±2	0.11	0.24
SPAP, mmHg	25.2±4.2	24.6±4.4	23.7±4.9	0.51	0.31
FVC, 1	3.2±1.4	3.4±1.1	3.4±1	0.39	0.75
FVC, % predicted	103±16.0	92.1±14.5	94.5±17	0.09	0.32
FEV ₁ , l/sec	2.6±0.9	3.1±1.1	3.1±1.1	0.12	0.15
FEV ₁ , % predicted	79.1±16.8	94±15	96.2±17.7	0.05	0.03
FEV ₁ /FVC	77±8.1	92.1±6.1	92.2±6.3	0.01	0.01
VO ₂ /kg/min	3.6±0.8	3.6±0.8	3.6±0.85	1	0.96

RER	$0.78{\pm}0.07$	$0.79{\pm}0.07$	$0.78{\pm}0.08$	0.91	0.93
AV difference, l/l	0.06 ± 0.02	0.06 ± 0.02	0.06 ± 0.02	1	1

Unless otherwise specified, numbers represent mean±standard deviation.

PAD - peripheral arterial disease, CAD - coronary artery disease, NA - notapplicable, CAS - carotid artery stenosis, AAA - abdominal aortic aneurysm, ABI ankle brachial index, SBP - systolic blood pressure, BMI - body mass index, ACEI angiotensin converting enzyme inhibitors, EDV - end diastolic volume, ESV - endsystolic volume, LVEF - left ventricular ejection fraction, LVMI - left ventricularmass index, LAVI - left atria volume index, E - mitral early flow wave, A - mitrallate flow wave, DT - deceleration time, E' - mean mitral annulus tissue velocity, S' lateral tricuspid valve tissue velocity, SPAP - systolic pulmonary artery pressure,FVC - functional vital capacity, FEV₁ - forced expiratory volume in 1 sec, VO₂ oxygen consumption, RER - respiratory exchange ratio, AV difference - arteriovenous oxygen extraction.

	Baseline	Unloaded	AT	Peak	P value	P value	P value
					within	PAD+CAD	PAD+CAD
					group	vs CAD	vs Normal
EDV index, ml/m ²					<u> </u>		
PAD+CAD	68±9.7	76±9.5	77.1±9.3	75.3±9.8	0.03		
CAD	67.1±10.6	79.2±10	87.6±9.8	86.2±10.2	< 0.001	0.013	0.027
Normal	67.5±11.5	80.6±11.7	88.2±12	85.9±11.6	< 0.001		
ESV index, ml/m ²							
PAD+CAD	26.1±8.4	25.8±9	24.3±8.6	23.8±8.1	0.36		
CAD	25.2±8.7	24.5±8.1	23.2±9.5	21.1±8.8	0.17	0.44	0.39
Normal	24.9±8.9	21.3±9.6	23±9.2	20.5±9.7	0.27		
Stroke volume, ml							
PAD+CAD	73.3±8.1	89±11	95±10	86±10	0.0014		
CAD	71.5±8.5	92±11	104±9	97±10	< 0.001	0.025	0.028
Normal	74.3±10.7	92±13	103±11	98±11	< 0.001		
HR, bpm							
PAD+CAD	71.1±4.3	82±12.6	97.3±14.1	107.7±17.2	< 0.001		
CAD	72.5±5	86.3±13.2	99.6±13.3	119.8±14.4	< 0.001	0.036	< 0.001
Normal	78.7±7.2	88.1±14	116.7±15	138.5±18.9	< 0.001		
CO, l/min							
PAD+CAD	5.4±0.9	7.4±2	9.3±2.7	10.5±2.9	< 0.001		
CAD	5.2±0.85	7.5±2.1	10.3±2.4	12.7±2.2	< 0.001	0.029	0.017
Normal	5.4±1.05	7.8±3	11.9±2.8	13.2±3	< 0.001		
E/E' ratio							
PAD+CAD	12.1±2.7	13.2±3.1	16.6±4.3	15.8±4	0.034		
CAD	10.2±2.4	9.3±2.4	10.4±2.5	11.9±2.9	0.42	0.051	0.0013
Normal	8.3±3.1	9.6±4	9.1±3.8	9.1±4.1	0.61		
S', cm/sec							
PAD+CAD	8.2±1.8	8.1±2	8.6±1.6	8.8±1.9	0.66		
CAD	9.4±1.9	10.1±2.1	9.6±1.8	9.7±2	0.71	0.33	0.41
Normal	9.4±2	9.7±1.5	9.1±1.8	9.6±2.1	0.6		
SPAP, mmHg							
PAD+CAD	25.2±4.2	28.1±4.9	32.9±4.4	35±5.1	< 0.001		
CAD	24.6±4.4	24.2±4.8	28.6±3.8	30.2±4	0.11	0.042	0.13
Normal	23.7±4.9	22.6±5.2	27.1±4.6	31.6±6.3	0.018		
VO2, ml/kg/min							
PAD+CAD	3.6±0.8	6.1±1.4	$14.2{\pm}1.8$	14.9±2	< 0.001		
CAD	3.6±0.8	5.8±1.9	17.1±2.9	19.3±2.5	< 0.001	< 0.001	< 0.001
Normal	3.6±0.85	6.5±2.5	18.1±3.3	22±3.6	< 0.001		
O2 pulse,							
ml/kg/min							
PAD+CAD	4.6±1.3	6.2±1.9	8.2±1.8	8.1±2.2	< 0.001		

Table 2: Hemodynamic and metabolic indices along the stages of exercise

CAD	4.7±1.1	6.5±2	10±2.4	11.1±2	< 0.001	0.0024	0.0027
Normal	4.5±1.3	6.6±2.3	9.8±2.3	11.7±2.6	< 0.001		
AV difference, l/l							
PAD+CAD	0.06 ± 0.02	0.06 ± 0.03	$0.09{\pm}0.03$	$0.09{\pm}0.03$	0.043		
CAD	0.06 ± 0.02	0.07 ± 0.03	$0.12{\pm}0.03$	0.13 ± 0.03	< 0.001	0.031	0.038
Normal	0.06 ± 0.02	0.07 ± 0.03	$0.12{\pm}0.03$	$0.13{\pm}0.03$	< 0.001		

Numbers represent mean±standard deviation.

AT – anaerobic threshold, EDV – end diastolic volume, PAD – peripheral arterial disease, CAD – coronary artery disease, ESV – end systolic volume, HR – heart rate, CO – cardiac output, SPAP – systolic pulmonary artery pressure, VO2 – oxygen consumption, AV difference – arteriovenous oxygen extraction.



${\rm Chronotropic\,incompetence,\%}$



